Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says

By Reuters News

- The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats and rising uptake among men accelerate their use, researcher Worldpanel by Numerator said on Thursday.

  • UK households with at least one GLP‑1 user spent more than £1 billion less on groceries than expected in the year after adoption compared with households without a GLP-1 user, Worldpanel said

  • The proportion of British households with a user of GLP-1 drugs, such as Eli Lilly's LLY.N Mounjaro or Novo Nordisk's NOVOb.CO Wegovy, has risen from 6.3% in February this year to 8.5% in August

  • Growth is accelerating. In the six-month period, user numbers of GLP-1 injections and pills rose almost as much as they did in the whole of the previous year

  • Despite regulatory approval only coming in June, pills, account for 11.2% of UK GLP-1 users

  • Men are also driving growth, making up 32% of users, up from 23% in February

  • Worldpanel by Numerator is a global consumer data company. Its survey data of what British households buy drew from a total sample of 9,629

  • The £1 billion figure of displaced spending from Britain's grocery market is equivalent to £389 a year displaced from each user households' shopping baskets.

  • Spending on alcohol and crisps among users has fallen 15% more than in non-user households

  • In contrast, easy, portion-controlled options are gaining ground. Volume sales of frozen ready meals have risen 30% among users

  • Worldpanel said its estimates suggested that GLP-1 usage was set to surpass 10% of British households in 2027

($1 = 0.7578 pounds)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.